ARK Genomic Revolution ETF
ARKG
59 hedge funds and large institutions have $50.8M invested in ARK Genomic Revolution ETF in 2018 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 16 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 15
6% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 16
0.43% more ownership
Funds ownership: 19.37% → 19.8% (+0.43%)
0% more funds holding
Funds holding: 59 → 59 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
22% less capital invested
Capital invested by funds: $65.5M → $50.8M (-$14.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Arlington Capital Management
Arlington Heights,
Illinois
|
+$6.32M |
| 2 |
CFA
Carroll Financial Associates
Charlotte,
North Carolina
|
+$2.76M |
| 3 |
Financial Engines Advisors
Santa Clara,
California
|
+$2.51M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$1.3M |
| 5 |
Jane Street
New York
|
+$1.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Passport Capital
San Francisco,
California
|
-$3.34M |
| 2 |
PCM
Penserra Capital Management
Orinda,
California
|
-$2.36M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.8M |
| 4 |
Morgan Stanley
New York
|
-$1.49M |
| 5 |
LPL Financial
San Diego,
California
|
-$1.12M |
ARKG Hedge Fund Activity: Q4 2018 in Review
59 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in ARK Genomic Revolution ETF (ARKG) for Q4 2018, worth a combined $50.8M — down 22% from $65.5M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new ARKG positions and 16 closed out — a net gain of 1 holder — while 18 added to existing stakes and 15 trimmed.
The largest buyer was Arlington Capital Management, opening a new position worth an estimated $6.32M. The largest seller was Passport Capital, exiting entirely with an estimated $3.34M sold.
- 59 institutional investors held ARK Genomic Revolution ETF (ARKG) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $50.8M of ARK Genomic Revolution ETF stock for Q4 2018, down 22% quarter-over-quarter.
- 17 funds opened new ARK Genomic Revolution ETF positions in Q4 2018 and 16 closed out, a net change of +1 holder.
- The largest ARK Genomic Revolution ETF buyer in Q4 2018 was Arlington Capital Management, an estimated $6.32M added.
- The largest ARK Genomic Revolution ETF seller in Q4 2018 was Passport Capital, an estimated $3.34M sold.
Based on aggregated 13F filings for Q4 2018.